Intracranial Hemangiopericytomas: Recurrence, Metastasis, and Radiotherapy

Ankur R. Patel, Bruno C. Flores, Vin Shen Ban, Kimmo J. Hatanpaa, Bruce E. Mickey, Samuel L. Barnett

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background Intracranial hemangiopericytomas (HPCs) are characterized by high recurrence rates and extracranial metastases. Radiotherapy provides an adjunct to surgery, but the timing of therapy and the patients most likely to benefit remain unclear. Methods A retrospective review of 20 patients with HPC treated at the University of Texas Southwestern Medical Center between 1985 and 2014 was conducted. Recurrence and metastasis rates along with overall survival (OS) were characterized based on therapeutic approach and tumor pathology using Kaplan-Meier and Cox regression analyses. Results The mean age was 45.6 years (range: 19–77). Gross total resection (GTR) was achieved in 13 patients, whereas 5 patients underwent subtotal resection. Median follow-up was 91.5 months (range: 8–357). The 5-, 10-, and 15-year recurrence-free survival (RFS) rates were 61, 41, and 20%, respectively. Six patients developed metastases at an average of 113 months (range: 42–231). OS at last follow-up was 80%. Importantly, immediate postoperative adjuvant radiotherapy (IRT) did not influence RFS compared with surgery alone or OS compared with delayed radiotherapy at the time of recurrence. Conclusion HPCs have high recurrence rates necessitating close follow-up. Surgery remains an important first step, but the timing of radiotherapy for optimal control and OS remains uncertain.

Original languageEnglish (US)
JournalJournal of Neurological Surgery, Part B: Skull Base
DOIs
StateAccepted/In press - Jan 6 2017

Fingerprint

Hemangiopericytoma
Radiotherapy
Neoplasm Metastasis
Recurrence
Survival
Adjuvant Radiotherapy
Survival Rate
Regression Analysis
Pathology
Therapeutics
Neoplasms

Keywords

  • hemangiopericytoma
  • intracranial
  • radiotherapy
  • recurrence
  • survival

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

@article{89f19a8cfd4b4838bdd02a5c87336b9b,
title = "Intracranial Hemangiopericytomas: Recurrence, Metastasis, and Radiotherapy",
abstract = "Background Intracranial hemangiopericytomas (HPCs) are characterized by high recurrence rates and extracranial metastases. Radiotherapy provides an adjunct to surgery, but the timing of therapy and the patients most likely to benefit remain unclear. Methods A retrospective review of 20 patients with HPC treated at the University of Texas Southwestern Medical Center between 1985 and 2014 was conducted. Recurrence and metastasis rates along with overall survival (OS) were characterized based on therapeutic approach and tumor pathology using Kaplan-Meier and Cox regression analyses. Results The mean age was 45.6 years (range: 19–77). Gross total resection (GTR) was achieved in 13 patients, whereas 5 patients underwent subtotal resection. Median follow-up was 91.5 months (range: 8–357). The 5-, 10-, and 15-year recurrence-free survival (RFS) rates were 61, 41, and 20{\%}, respectively. Six patients developed metastases at an average of 113 months (range: 42–231). OS at last follow-up was 80{\%}. Importantly, immediate postoperative adjuvant radiotherapy (IRT) did not influence RFS compared with surgery alone or OS compared with delayed radiotherapy at the time of recurrence. Conclusion HPCs have high recurrence rates necessitating close follow-up. Surgery remains an important first step, but the timing of radiotherapy for optimal control and OS remains uncertain.",
keywords = "hemangiopericytoma, intracranial, radiotherapy, recurrence, survival",
author = "Patel, {Ankur R.} and Flores, {Bruno C.} and Ban, {Vin Shen} and Hatanpaa, {Kimmo J.} and Mickey, {Bruce E.} and Barnett, {Samuel L.}",
year = "2017",
month = "1",
day = "6",
doi = "10.1055/s-0037-1599073",
language = "English (US)",
journal = "Journal of Neurological Surgery, Part B: Skull Base",
issn = "2193-6331",
publisher = "Thieme Medical Publishers",

}

TY - JOUR

T1 - Intracranial Hemangiopericytomas

T2 - Recurrence, Metastasis, and Radiotherapy

AU - Patel, Ankur R.

AU - Flores, Bruno C.

AU - Ban, Vin Shen

AU - Hatanpaa, Kimmo J.

AU - Mickey, Bruce E.

AU - Barnett, Samuel L.

PY - 2017/1/6

Y1 - 2017/1/6

N2 - Background Intracranial hemangiopericytomas (HPCs) are characterized by high recurrence rates and extracranial metastases. Radiotherapy provides an adjunct to surgery, but the timing of therapy and the patients most likely to benefit remain unclear. Methods A retrospective review of 20 patients with HPC treated at the University of Texas Southwestern Medical Center between 1985 and 2014 was conducted. Recurrence and metastasis rates along with overall survival (OS) were characterized based on therapeutic approach and tumor pathology using Kaplan-Meier and Cox regression analyses. Results The mean age was 45.6 years (range: 19–77). Gross total resection (GTR) was achieved in 13 patients, whereas 5 patients underwent subtotal resection. Median follow-up was 91.5 months (range: 8–357). The 5-, 10-, and 15-year recurrence-free survival (RFS) rates were 61, 41, and 20%, respectively. Six patients developed metastases at an average of 113 months (range: 42–231). OS at last follow-up was 80%. Importantly, immediate postoperative adjuvant radiotherapy (IRT) did not influence RFS compared with surgery alone or OS compared with delayed radiotherapy at the time of recurrence. Conclusion HPCs have high recurrence rates necessitating close follow-up. Surgery remains an important first step, but the timing of radiotherapy for optimal control and OS remains uncertain.

AB - Background Intracranial hemangiopericytomas (HPCs) are characterized by high recurrence rates and extracranial metastases. Radiotherapy provides an adjunct to surgery, but the timing of therapy and the patients most likely to benefit remain unclear. Methods A retrospective review of 20 patients with HPC treated at the University of Texas Southwestern Medical Center between 1985 and 2014 was conducted. Recurrence and metastasis rates along with overall survival (OS) were characterized based on therapeutic approach and tumor pathology using Kaplan-Meier and Cox regression analyses. Results The mean age was 45.6 years (range: 19–77). Gross total resection (GTR) was achieved in 13 patients, whereas 5 patients underwent subtotal resection. Median follow-up was 91.5 months (range: 8–357). The 5-, 10-, and 15-year recurrence-free survival (RFS) rates were 61, 41, and 20%, respectively. Six patients developed metastases at an average of 113 months (range: 42–231). OS at last follow-up was 80%. Importantly, immediate postoperative adjuvant radiotherapy (IRT) did not influence RFS compared with surgery alone or OS compared with delayed radiotherapy at the time of recurrence. Conclusion HPCs have high recurrence rates necessitating close follow-up. Surgery remains an important first step, but the timing of radiotherapy for optimal control and OS remains uncertain.

KW - hemangiopericytoma

KW - intracranial

KW - radiotherapy

KW - recurrence

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85014077509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014077509&partnerID=8YFLogxK

U2 - 10.1055/s-0037-1599073

DO - 10.1055/s-0037-1599073

M3 - Article

C2 - 28725519

AN - SCOPUS:85014077509

JO - Journal of Neurological Surgery, Part B: Skull Base

JF - Journal of Neurological Surgery, Part B: Skull Base

SN - 2193-6331

ER -